An Ounce of Prevention
Exploring Nonfactor Therapies in Hemophilia
Concizumab prophylaxis in people with hemophilia A or hemophilia B without inhibitors (explorer8): a prospective, multicenter, open-label, randomized, phase 3a trial.
Chowdary P, et al. Lancet Hematol. 2024;11(12):e891-e904.
International Society of Thrombosis and Hemostasis (ISTH) 2025 Online Congress Program Abstracts.
Efficacy and safety pf the anti-tissue factor pathway inhibitor marstacimab in participants with severe hemophilia without inhibitors: results form the phase 3 BASIS trial.
Matino D, et al. Blood. 2023;142(suppl 1):285.
Phase 3 trial of concizumab in hemophilia with inhibitors.
Matsushita T, et al. N Engl J Med. 2023;389(9): 783-794.
Long-term safety and efficacy of fitusiran prophylaxis, and perioperative management, in people with hemophilia A or B.
Pipe SW, et al. Blood Adv. 2025;9(5):1147-1158.
Clinical Practice Guidelines
World Federation of Hemophilia (WFH) Guidelines for the Management of Hemophilia. 3rd Edition.
Srivastava A, et al. Hemophilia. 2020;26(suppl 6):1-158.
Patient Advocacy Organizations and Resources
Hemophilia Federation of America (HFA)
The HFA is a patient advocacy organization serving the rare bleeding disorders community. It is a community-based, patient-centered organization committed to championing the needs of families living with debilitating bleeding disorders. It advocates for safe and effective therapies and quality, affordable health coverage.
National Bleeding Disorders Foundations (NBDF)
The NBDF (formerly the National Hemophilia Foundation) is dedicated to finding cures for inheritable blood and bleeding disorders and to addressing and preventing the complications of these disorders through research, education, and advocacy enabling people and families to thrive.
WFH
The WFH is a non-profit organization dedicated to improving and sustaining care for people with inherited bleeding disorders around the world.
Hemophilia and the Coagulation Cascade
Module 1
| Faculty: | Stacy E. Croteau, MD, MMS; Guy Young, MD |
| Release: | 08/28/2025 |
| Expiration: | 08/28/2026 |
Individualized Nonfactor Therapy for Hemophilia
Module 2
| Faculty: | Stacy E. Croteau, MD, MMS; Guy Young, MD |
| Release: | 08/28/2025 |
| Expiration: | 08/28/2026 |
